US Patent 7052691 Methods of treating diabetes by blocking VEGF-mediated activity
Patent 7052691 was granted and assigned to Regeneron Pharmaceuticals on May, 2006 by the United States Patent and Trademark Office.
All edits
Edits on 28 Aug, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 2 Mar, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 21 Nov, 2023
Golden AI
Edits made to:
Infobox (+10 properties)
Article (+253 characters)
Article
Patent abstract
Methods of treating diabetes in mammals, particularly humans, by blocking or inhibiting VEGF-mediated activity. A preferred inhibitor of VEGF-mediated activity is a VEGF antagonist such as a VEGF trap capable of binding and blocking VEGF.
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
Patent Inventor Names
Mark W. Sleeman0
Stanley J. Wiegand0
Date of Patent
May 30, 2006
0Patent Application Number
108111700
Date Filed
March 26, 2004
0Patent Primary Examiner
Golden AI
Edits made to:
US Patent 7052691 Methods of treating diabetes by blocking VEGF-mediated activity
Find more entities like US Patent 7052691 Methods of treating diabetes by blocking VEGF-mediated activity
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
